Renin-angiotensin-aldosterone System (RAAS) Blockade and Contrast Induced Nephropathy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01525888

Enrollment

100

Registered

2012-02-03

Start date

2012-02-29

Completion date

2013-12-31

Last updated

2015-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiographic Contrast Agent Nephropathy

Keywords

Contrast induced nephropathy

Brief summary

The aim of the current study is to evaluate prospectively whether concomitant administration of renin-angiotensin-aldosterone system (RAAS) blockers (namely ACE-I and ARBs') influence the change in estimated glomerular filtration rate or GFR (eGFR) after administration of contrast media in patients undergoing non-emergent coronary angiography.

Detailed description

Contrast-induced nephropathy (CIN) is defined as an absolute or relative increase in serum creatinine compared to the baseline values, together with exposure to a contrast agent and exclusion of alternative explanations for renal impairment. Most frequently the renal impairment develops 48 hours post exposure. Although RAAS blocking agents are widely used among patients requiring contrast studies, data regarding the effect of these agents on the development of CIN are sparse and inconsistent. Patients undergoing percutaneous coronary intervention are frequently treated with RAAS blocking agents. Despite the not infrequent occurrence of CIN following percutaneous coronary intervention (PCI) no guidelines are available on the topic of the cessation of the RAAS inhibitors prior to the procedure.

Interventions

PROCEDUREstop angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB)

stoping for 6 days treatment with angiotensin converting enzyme inhibitor or angiotensin receptor blocker

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age \> 18 years, * chronic therapy with ACE-I and/or ARBs' (confirmed by electronic records in their medical file) and * planned coronary angiography

Exclusion criteria

* chronic utilization of NSAIDS and Cox-2 selective inhibitors, * chronic treatment with mineralocorticosteroid receptor blocker, and * administration of contrast within 14 days prior to the enrollment.

Design outcomes

Primary

Measure	Time frame
change in eGFR from baseline to 48-72 hours following the exposure to the contrast.	48 AND 72 HOURS AFTER EXPOSURE TO CONTRAST MEDIA

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026